Author:
Khattak Muhammad A.,Luke Jason J.,Long Georgina V.,Ascierto Paolo A.,Rutkowski Piotr,Schadendorf Dirk,Robert Caroline,Grob Jean-Jacques,de la Cruz Merino Luis,Del Vecchio Michele,Spagnolo Francesco,Mackiewicz Jacek,Chiarion-Sileni Vanna,Carlino Matteo S.,Mohr Peter,De Galitiis Federica,Ross Merrick I.,Eroglu Zeynep,Chen Ke,Jiang Ruixuan,Fukunaga-Kalabis Mizuho,Krepler Clemens,Eggermont Alexander M.M.,Kirkwood John M.
Reference17 articles.
1. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial;Luke;Lancet,2022
2. FDA approves pembrolizumab for adjuvant treatment of stage IIB or IIC melanoma;US Food and Drug Administration,2021
3. NCCN clinical practice guidelines in oncology (NCCN guidelines): melanoma: cutaneous;National Comprehensive Cancer Network,2022
4. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual;Gershenwald;CA Cancer J Clin,2017
5. NCCN clinical practice guidelines in oncology (NCCN guidelines): melanoma: cutaneous;National Comprehensive Cancer Network,2021
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献